key: cord-0072866-ch37peh7
authors: Pranata, Raymond; Huang, Ian; Lim, Michael Anthonius; Yonas, Emir; Vania, Rachel; Lukito, Antonia Anna; Nasution, Sally Aman; Siswanto, Bambang Budi; Kuswardhani, Raden A. Tuty
title: Elevated De Ritis Ratio Is Associated With Poor Prognosis in COVID-19: A Systematic Review and Meta-Analysis
date: 2021-12-22
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.676581
sha: 5093967744fe9f00fbd41d0a512b2cacfcdd36f1
doc_id: 72866
cord_uid: ch37peh7

Objective: This meta-analysis aims to assess whether elevated De Ritis ratio is associated with poor prognosis in patients with coronavirus 2019 (COVID-19). Methods: A systematic literature search was performed using PubMed, Embase, and EuropePMC databases up until September 17, 2021. De Ritis ratio is also known as Aspartate aminotransferase/alanine transaminase (AST/ALT) ratio. The main outcome was poor prognosis, a composite of mortality, severity, the need for ICU care, and intubation. The effect measure was odds ratios (ORs) and mean differences. We generated sensitivity and specificity, negative and positive likelihood ratio (NLR and PLR), diagnostic odds ratio (DOR), and area under curve (AUC). Results: There were eight studies with 4,606 patients. De Ritis ratio was elevated in 44% of the patients. Patients with poor prognosis have higher De Ritis ratio [mean difference 0.41 (0.31, 0.50), p < 0.001; I(2): 81.0%] and subgroup analysis showed that non-survivors also have higher De Ritis Ratio [mean difference 0.47 (0.46, 0.48), p < 0.001; I(2): 0%]. Elevated De Ritis ratio was associated with poor prognosis [OR 3.28 (2.39, 4.52), p < 0.001; I(2): 35.8%]. It has a sensitivity of 55% (36–73), specificity of 71% (52–85), PLR 1.9, NLR.63, DOR of 3 (2–4), and AUC of.67 (0.63–0.71). The posterior probability of poor prognosis was 38% if De Ritis is elevated, while 17% if De Ritis is not elevated. Conclusion: Elevated De Ritis ratio is associated with poor prognosis in patients with COVID-19. Systematic Review Registration: PROSPERO ID: CRD42020216634.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and causes a considerable number of deaths worldwide (1) . Although most patients with coronavirus 2019 disease (COVID- 19) have mild-to-moderate symptoms, they may develop severe COVID-19 with multi-organ dysfunction, cardiorespiratory collapse, coagulopathy and thrombosis, sepsis, and even death (2, 3) . Common symptoms include fever, cough and dyspnea, and minor symptoms are dysgeusia, anosmia, gastrointestinal symptoms, cutaneous manifestation, and headache (4) (5) (6) . Although the virus primarily affects the lungs, it may invade and damage other organs, such as the heart and vasculature, coagulation system, liver, kidneys, intestine, and central nervous system (7) (8) (9) (10) (11) (12) .

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported to cause a varying degree of liver injury (13) . Liver injury is more frequently found in patients with severe COVID-19 and is associated with an increased risk of poor outcomes (14) . The ratio between the two most routinely requested liver function panel, the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio or more commonly known as the De Ritis ratio, was recently reported as a possible biomarker for prognostication in patients with COVID-19 (15) . Therefore, we conducted a systematic review and meta-analysis to evaluate the association between De Ritis ratio and composite poor outcomes in COVID-19.

The study was registered in the PROSPERO database (CRD42020216634) and was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Research articles (both prospective and retrospective cohorts) that contain information on De Ritis ratio and mortality, severity, intensive care unit (ICU) care admission or need for intubation were included in the study. We excluded preprints, review articles, editorial, commentaries, conference abstracts, letters, and case reports/series.

We performed a systematic literature search from PubMed database, Embase database, and EuropePMC database with the search terms "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" AND "De Ritis Ratio" OR "AST ALT Ratio. and exclusion criteria served as the basis for article exclusion during the title or abstract screening and evaluation of fulltext articles.

Data extraction from the eligible studies was conducted by two authors who are independently using pre-built forms containing the author, study design, origin, AST, ALT, cut-off for elevated De Ritis ratio, sample size, age, gender, obesity, diabetes, elevated liver enzymes, and outcome of interests.

The main outcome was poor prognosis, a composite of mortality, severity, need for ICU care, and need for intubation. Mortality was defined as non-survivor or death.

Severity was defined according to the studies inclusion parameters, need for ICU care, and intubation. The effect measure was the odds ratios (ORs) and mean differences. Diagnostic meta-analysis was performed to generate diagnostic values, which consisted of sensitivity, specificity, negative and positive likelihood ratio (NLR and PLR), diagnostic odds ratio (DOR), and area under curve (AUC).

The risk of bias assessment was performed independently by two authors with the help of Newcastle-Ottawa Scale (NOS). Discrepancies were resolved by discussion. The Egger's test and Deek's funnel plot asymmetry test was used to assess the presence of small-study effects and publication bias, respectively.

STATA 16 (College Station, TX) was used to perform statistical analysis. Meta-analysis of proportions was performed to pool the incidence of elevated De Ritis Ratio. DerSimonian and Laird method random-effects models were used to pool ORs and mean differences, notwithstanding heterogeneity. p < 0.05 were considered statistically significant. Inter-study heterogeneity was evaluated using the I-squared (I 2 ) and Cochrane Q test, an I 2 > 50% or p < 0.10 indicates substantial heterogeneity. We performed pooling of sensitivity and specificity and generated a summary receiver operating characteristic (SROC) curve. Relationship between prior probability and posterior probability was evaluated using Fagan's nomogram. Subgroup analysis was performed for mortality outcome.

There were eight studies with 4,606 patients in this meta-analysis ( Figure 1 ) (7, (16) (17) (18) (19) . The mean age of patients in this study was 64.3 years, whereas 46.3% of the patients were male. The characteristics of the studies are presented in Table 1 

Newcastle-Ottawa Scale (NOS) indicates a low-moderate risk of bias ( Table 1) . There is no indication of small-study effects in the relationship between elevated De Ritis ratio and poor 

Early identification of patients at risk for developing severe COVID-19 is crucial during the pandemic. Previous studies highlighted that individuals with advanced age, high body mass index, and physical inactivity had greater morbidity and mortality from COVID-19, along with the presence of various comorbidities, such as cardiovascular disease, diabetes, chronic obstructive pulmonary disease, hypertension, and chronic kidney disease (23) (24) (25) (26) (27) (28) (29) (30) (31) . Several inflammatory parameters, comprising C-reactive protein, D-dimer, procalcitonin, interleukin-6, and ferritin, are often higher in patients with severe and critically ill with COVID-19 (8) . An increase in liver-related biomarkers, particularly AST, ALT, total bilirubin concentrations, and gamma-glutamyl transferase in patients with COVID-19 have been reported (32, 33) . Although hepatic damage is not commonly seen as a major characteristic of COVID-19, liver injury is an emerging concern because it may indicate a severe disease course (2). The mechanism for liver involvement in COVID-19 remains obscure. Previous liver pathology reports showed the presence of moderate microvesicular steatosis along with mild inflammation in several areas (34) . These patterns are also observed in druginduced liver injury and sepsis, although these findings are not unique, they might provide insight into the mechanism involved in liver injury induced by COVID-19 (35) . The SARS-CoV-2 may invade the liver directly through the angiotensin receptor enzyme 2 (ACE2) receptor, which serves as the novel coronavirus' entry point. It has been found that bile duct epithelial cells (cholangiocytes) express a high amount of ACE2 receptors (36) . Liver dysfunction may also be caused by druginduced liver injury or an overactive inflammatory response, including cytokine storm and pneumonia-associated hypoxia (2, 7) . Antivirals used in the treatment of COVID-19 are postulated to cause drug-induced liver injury (37) .

Serum concentrations of ALT and AST, without exception, are the most frequently ordered liver panel for evaluating liver injury in all laboratories. ALT is present in the cytosol of hepatocytes, while AST is present in the cytoplasm and mitochondria of the hepatocyte (38) . ALT activity in the liver is ∼10-fold higher than that of the heart and skeletal muscles, which emphasizes its function to indicate parenchymal liver disease or injury. Meanwhile, AST has the greatest activity in the liver, cardiac, and skeletal muscle, but also exhibits in other tissues including kidneys, pulmonary, brain, pancreas, red blood cells, and white blood cells. Therefore, ALT is a more specific biomarker for liver damage compared to AST, indicating liver-biliary disease, myocardial injury, and rhabdomyolysis (7, 15) . AST and ALT are found in the liver with a 2.5:1 ratio but with different turnaround time, resulting in a relatively similar level of serum of AST and ALT in healthy populations (38) .

The De Ritis ratio or the AST/ALT ratio is a promising biochemical parameter for prognostication in COVID-19. In the present study, elevated De Ritis ratio was associated with 3fold increased risk for poor prognosis in patients with COVID-19. Although the cut-off values for elevated De Ritis ratio are different from these five studies (Table 1) , the result of this meta-analysis has low heterogeneity (I 2 : 35.8%). Nonetheless, the difference in the cut-off value used between those studies caused a highly varied diagnostic value (Figure 3) with an overall sensitivity of 55%, specificity of 71%, and AUC of 0.67. These variations further translate into the uncertainty of the optimal cut-off value for De Ritis Ratio as a prognostic factor in COVID-19 and merit further investigations. Interestingly, Qin et al. indicated that De Ritis ratio of ≥1.38 was independently associated with poor prognosis irrespective of AST elevation (≤40 and >40 U/L) (16) . They showed that AST/ALT ratio elevation was associated with a more severely computed tomography scan findings, higher severity, and positive linear association with other prognostic markers (e.g., c-reactive protein, procalcitonin, interleukin-6, D-Dimer, lactate, LDH, and creatine Kinase-MB). Additionally, Chen et al. showed the association of AST/ALT ratio with liver injury and severity of COVID-19. However, the number of outcomes or risk estimates (e.g., OR) of this study interest was not available (18) .

There were two studies on the association of De Ritis ratio with other specific biochemical parameters (e.g., creatinine kinase and serum ALT), but were excluded from the analysis due to its irrelevance with our outcome of interest (15, 39) .

The limitations of the current study were primarily caused by the small quantity of the included studies. Moreover, the retrospective-observational nature and the small sample size of the included studies should be taken into account in extrapolating the results of this metaanalysis, where selection bias and confounding factors may be evident. We also could not dismiss the possibility of publication bias due to the small number of studies. Despite our limitations, this meta-analysis has brought early evidence of using the De Ritis ratio for prognostication in COVID-19.

Although this "traditional" ratio was initially found in 1957 as a diagnostic test for viral hepatitis (40) , it is still commonly used and proves to be a valuable indicator of liver disease (38) . It is a promising, straightforward, and readily available parameter for poor prognosis in COVID-19. This meta-analysis showed that AST, but not ALT, was significantly associated with poor prognosis in COVID-19. This supports the use of De Ritis ratio in addition to AST and ALT levels. However, we suggest, including this parameter and other accessible hematological markers, to improve the prognostic performance of the model for COVID-19. De Ritis ratio would be better for this marker to be a part of a prognostic model rather than a stand-alone examination. A predictive model comprising of readily available tools may be of value, especially in rural areas where sophisticated prognostic biomarkers are often not available.

In conclusion, elevated De Ritis ratio is associated with poor prognosis in patients with COVID-19.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

RP: conceptualization, methodology, formal analysis, investigation, and writing-original draft. IH: data curation, investigation, writing-original draft, and project administration. ML: data curation, investigation, and writingoriginal draft. EY and RV: investigation and writing-original draft. AL, SN, BS, and RK: investigation and writing-review and editing. All authors contributed to the article and approved the submitted version.

Coronavirus Disease

multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis

The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review

Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases

Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy

Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes

The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients

Creactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Endotheliopathy marked by high von Willebrand Factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis

Left and right ventricular longitudinal strains are associated with poor outcome in COVID-19: a systematic review and meta-analysis

Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: a systematic review and meta-analysis

Prognostic performance of troponin in COVID-19: a diagnostic meta-analysis and metaregression

COVID-19, MERS and SARS with concomitant liver injury-systematic review of the existing literature

Fibrosis-4 index and mortality in coronavirus disease 2019

De Ritis ratio and biochemical parameters in COVID-19 patients

High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients

The effect of liver test abnormalities on the prognosis of COVID-19

Clinical features and risk factors of COVID-19-associated liver injury and function: a retrospective analysis of 830 cases

Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report

Abnormal liver function test in patients infected with coronavirus (SARS-CoV-2): a retrospective single-center study from Spain

Proinflammatory and hepatic features related to morbidity and fatal outcomes in COVID-19 patients

Prevailing patterns of liver enzymes in patients with COVID-19 infection and association with clinical outcomes

Severity of COVID-19 in end-stage kidney disease patients on chronic dialysis

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression: diabetes and COVID-19

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, metaanalysis, and meta-regression

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

Body mass index and outcome in patients with COVID-19: a dose-response metaanalysis

Effect of heart failure on the outcome of COVID-19 -a meta analysis and systematic review

The association between chronic kidney disease and new onset renal replacement therapy on the outcome of COVID-19 patients: a meta-analysis

Diabetes and COVID-19: the past, the present, and the future

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Liver injury in COVID-19: the current evidence

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv

COVID-19 and the digestive system

The de ritis ratio: the test of time

Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19)

An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.